Schizophrenia--biological consideration
Shimazono, Y.
Seishin Shinkeigaku Zasshi 78(4): 251-256
1976
ISSN/ISBN: 0033-2658 PMID: 989916 Document Number: 99153
Document emailed within 1 workday
Related Documents
Omori, T. 2011: Drug therapy of schizophrenia with cognitive function and QOL taken into consideration Seishin Shinkeigaku Zasshi 113(1): 111-116Shirakawa, S.; Kita, K.; Kobayashi, T.; Ohno, T.; Matsuoka, N. 1986: Treatment of malignant lymphoma under consideration of its biological behavior Gan to Kagaku Ryoho. Cancer and ChemoTherapy 13(9): 2734-2744
Favier, M.; Meddoun, M.; Hoffmann, P.; Ayoubi, J.M. 2000: Measuring the risk of infection after premature rupture of the membranes: consideration of complemenatary examinations and biological markers? Gynecologie Obstetrique and Fertilite 28(12): 940-942
Otsuki, S. 1983: Schizophrenia--a biological approach Seishin Shinkeigaku Zasshi 85(10): 652-655
Munkvad, I. 1977: Biological schizophrenia research Ugeskrift for Laeger 139(45): 2687-2688
Gazdag, G.; Ungvari, G.S. 2011: Non-pharmacological biological therapies in schizophrenia Neuropsychopharmacologia Hungarica: a Magyar Pszichofarmakologiai Egyesulet Lapja 13(4): 233-238
Mikolaĭskiĭ, M.V. 1985: Relation between biological and social factors in the differentiation of clinical forms of the course of schizophrenia Vrachebnoe Delo 11: 103-105
Beck-Bornholdt, H.P.; Schmidt, R.; Schwarz, R.C.; Hübener, K.H. 1991: Biological isoeffect distributions: consideration of the influence of dose per fraction and overall treatment time. A possible tool in future treatment planning Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft . 167(12): 708-715
Morera, A.L.; Henry, M.; García-Hernández, A.; Fernández-López, L. 2007: Acute phase proteins as biological markers of negative psychopathology in paranoid schizophrenia Actas Espanolas de Psiquiatria 35(4): 249-252
Schooler, N.R.; Keith, S.J.; Severe, J.B.; Matthews, S. 1989: Acute treatment response and short term outcome in schizophrenia: first results of the NIMH treatment strategies in schizophrenia study. Treatment Strategies in Schizophrenia Collaborative Study Group Psychopharmacology Bulletin 25(3): 331-335
Roxo, H. 1952: Pseudoneurotics; patients at the onset of schizophrenia; differential diagnosis of neurasthenia and schizophrenia; modern therapy Imprensa Medica 28(463): 25-30
Zaytseva, Y.; Burova, V.; Garakh, Z.; Gurovich, I.Y. 2013: Attributional style in fist episode of schizophrenia and schizophrenia spectrum disorders with and without paranoid ideation Psychiatria Danubina 25(Suppl 2): S329-S331
Kotlicka-Antczak, M.; Rabe-Jabłońska, J. 1997: Neurodevelopmental schizophrenia: the concept of developmental origins of certain forms of schizophrenia Psychiatria Polska 31(5): 527-538
Tsirkin, S.Iu. 1987: International study of schizophrenia based on a WHO program. Incidence of schizophrenia Zhurnal Nevropatologii i Psikhiatrii Imeni S.S. Korsakova 87(8): 1203-1207
Arraras, J.I.; Basterra, I.; Pereda, N.; Ibañez, B.; Iribarren, S.; Cabases, J.M. 2019: The Schizophrenia Quality of Life Scale Revision 4 (SQLS-R4) questionnaire. A validation study with Spanish schizophrenia spectrum outpatients Actas Espanolas de Psiquiatria 47(3): 97-109
Suzuki, S. 1982: The mental maturation and verbal alteration in a mild case of chronic non-paranoiac schizophrenia. a linguistic-phenomenological approach to the concept of schizophrenia simplex Seishin Shinkeigaku Zasshi 84(1): 1-19
Hargreaves, W.A.; Kane, J.M.; Ninan, P.T.; Severe, J.B.; Woerner, M. 1989: Demographic characteristics, treatment history, presenting psychopathology and early course in schizophrenia. Treatment Strategies in Schizophrenia Collaborative Study Group Psychopharmacology Bulletin 25(3): 340-343
Williams, J.; Spurlock, G.; McGuffin, P.; Mallet, J.; Nöthen, M.M.; Gill, M.; Aschauer, H.; Nylander, P.O.; Macciardi, F.; Owen, M.J. 1996: Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. European Multicentre Association Study of Schizophrenia (EMASS) Group Lancet 347(9011): 1294-1296
Keefe, R.S.; Mohs, R.C.; Davidson, M.; Losonczy, M.F.; Silverman, J.M.; Lesser, J.C.; Horvath, T.B.; Davis, K.L. 1988: Kraepelinian schizophrenia: a subgroup of schizophrenia? Psychopharmacology Bulletin 24(1): 56-61
Glick, I.D.; Jacobs, M.; Lieberman, J.; Simpson, G.; Schooler, N.R. 1989: Prediction of short term outcome in schizophrenia: depressive symptoms, negative symptoms, and extrapyramidal signs. Treatment Strategies in Schizophrenia Collaborative Study Group Psychopharmacology Bulletin 25(3): 344-347